Alarelin Dihexa Follistatin 344 GHRP-2 Gonadorelin Hexarelin HGH Fragment 176-191 Liraglutide Mechano Growth Factor N-Acetyl Semax PEG-MGF Pentosan Polysulfate Triptorelin Recently Updated These protocols were most recently reviewed or updated with new data: July 2026: Adamax: Published full nootropic Semax-analog protocol with evidence limits, route context, reconstitution math, and Orbitrex supplies planning June 2026: GHRP-6: Published full GH secretagogue protocol with saturation-dose context, empty-stomach timing, reconstitution math, stack comparisons, and Ion Peptide supplies planning June 2026: VIP: Published full vasoactive intestinal peptide protocol with nasal vs subcutaneous context, lipase monitoring, reconstitution math, and Peptide Partners supplies planning June 2026: FOXO4-DRI: Published full senolytic research protocol with animal-dose context, community-cycle boundaries, reconstitution math, and supplies planning June 2026: Epitalon (Epithalon): Published full AEDG bioregulator protocol with cycle planning, reconstitution math, supplies guidance, and telomere evidence boundaries June 2026: Glutathione: Published full antioxidant protocol with oral, liposomal, intranasal, and IV route context plus supplies planning June 2026: 5-Amino-1MQ: Published full NNMT inhibitor protocol with oral dosing, optional subcutaneous vial math, reconstitution guidance, and supplies planning June 2026: Survodutide: Published full dual GLP-1/glucagon protocol with Phase 2 and Phase 3 trial context, reconstitution math, and supplies planning June 2026: Pinealon: Published full EDR tripeptide protocol with oral/SubQ planning, reconstitution math, and supplies guidance June 2026: Humanin: Published full mitochondrial-derived peptide protocol with HNG evidence boundaries, reconstitution math, and supplies planning June 2026: Thymosin Alpha-1: Published full immune-modulation protocol with twice-weekly dosing, reconstitution, and clinical-trial coverage June 2026: SS-31 (Elamipretide): Published full mitochondria-targeting protocol with dosing, reconstitution, and clinical program review June 2026: KPV: Updated anti-inflammatory mechanism section and community dosing notes June 2026: Retatrutide: Added TRIUMPH Phase 3 interim data references June 2026: BPC-157: Updated regulatory status following FDA Category 2 Category 1 reclassification June 2026: TB-500: Updated regulatory status following FDA reclassification All protocols carry a Last reviewed date
Cost remains high for brand-name formulations
Some part of me, oddly, needed reconciliation with him
Children may need lower doses
Heres how to decide: Once daily (evening): Best for scalp health maintenance, lower concentrations (23%), or if youre just starting out
